Bausch + Lomb Corp.

BLCO

Summary

more
Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$18.00 35,000,000 Positive High 42.84%

Offering Team

Deal Managers

  • Morgan Stanley
  • Goldman Sachs
  • Citigroup

Lawyers

  • Davis Polk & Wardwell LLP

Auditors

  • PricewaterhouseCoopers LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world—from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Our comprehensive portfolio of over 400 products is fully integrated and built to serve our customers across the full spectrum of their eye health needs throughout their lives. Our iconic brand is built on the deep trust and loyalty of our customers established over our nearly 170-year history. We have a significant global research, development, manufacturing and commercial footprint of approximately 12,500 employees and a presence in approximately 100 countries, extending our reach to billions of potential customers across the globe. We have long been associated with many of the most significant advances in eye health, and we believe we are well positioned to continue leading the advancement of eye health in the future. Our iconic and enduring brands are among the most recognized and most trusted in the industry. Since our beginnings in 1853 as an optical goods shop in Rochester, New York, we have remained focused on advancing eye health for people all over the world. Among our many innovations over the years, we introduced the first optical glass in the United States, the lenses used on cameras to take the first satellite picture of the moon, and the first mass-produced soft contact lens in 1971. As part of our longstanding commitment to eye care professionals and the patients they serve, we invest in physician training, patient and customer education, disease prevention and other initiatives through both traditional and digital platforms to continue to advance eye health. As a result of this legacy, we believe our brand is synonymous with eye health among patients, consumers and professionals around the world.

Deal Tracker

Investors

Filing

28 Apr, 2022

Offer

06 May, 2022

Look Ahead

Lock Up Expiry

06 Nov, 2022

Earning

Nov 1, 2018

IPO Terms

Offer Price $18.00
Offer Size 35M

Market Sentiments

Stock Price